Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Hartley

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Trials|January 14, 2024
CompARE: study protocol for a phase III randomised controlled platform trial comparing alternative regimens for escalating treatment of intermediate and high-risk oropharyngeal cancerHisham Mehanna, Piers Gaunt, Anthony Kong, et al.
Cancers|April 3, 2021
Safety and Treatment Outcomes of Nivolumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Retrospective Multicenter Cohort StudyIfigenia Vasiliadou, Omar Breik, Holly Baker, et al.
European Journal of Cancer (Oxford, England : 1990)|November 13, 2017
COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-lossSimon J Crabb, Karen Martin, Julia Abab, et al.
Clinical and Translational Radiation Oncology|July 6, 2021
A multi-centre survey reveals variations in the standard treatments and treatment modifications for head and neck cancer patients during Covid-19 pandemicIfigenia Vasiliadou, David Noble, Andrew Hartley, et al.
Lancet (London, England)|November 20, 2018
Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trialHisham Mehanna, Max Robinson, Andrew Hartley, et al.
Nature|November 19, 2025
Hepatic zonation determines tumorigenic potential of mutant β-cateninAlexander Raven, Kathryn Gilroy, Hu Jin, et al.
International Journal of Cancer|April 30, 2024
The use of pembrolizumab monotherapy for the management of head and neck squamous cell carcinoma (HNSCC) in the UKIfigenia Vasiliadou, Derek Grose, Christina Wilson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 23, 2023
Developing and Validating a Multivariable Prognostic-Predictive Classifier for Treatment Escalation of Oropharyngeal Squamous Cell Carcinoma: The PREDICTR-OPC StudyHisham Mehanna, Davy Rapozo, Sandra V von Zeidler, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Trials|January 14, 2024
CompARE: study protocol for a phase III randomised controlled platform trial comparing alternative regimens for escalating treatment of intermediate and high-risk oropharyngeal cancerHisham Mehanna, Piers Gaunt, Anthony Kong, et al.
Cancers|April 3, 2021
Safety and Treatment Outcomes of Nivolumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Retrospective Multicenter Cohort StudyIfigenia Vasiliadou, Omar Breik, Holly Baker, et al.
European Journal of Cancer (Oxford, England : 1990)|November 13, 2017
COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-lossSimon J Crabb, Karen Martin, Julia Abab, et al.
Clinical and Translational Radiation Oncology|July 6, 2021
A multi-centre survey reveals variations in the standard treatments and treatment modifications for head and neck cancer patients during Covid-19 pandemicIfigenia Vasiliadou, David Noble, Andrew Hartley, et al.
Lancet (London, England)|November 20, 2018
Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trialHisham Mehanna, Max Robinson, Andrew Hartley, et al.
Nature|November 19, 2025
Hepatic zonation determines tumorigenic potential of mutant β-cateninAlexander Raven, Kathryn Gilroy, Hu Jin, et al.
International Journal of Cancer|April 30, 2024
The use of pembrolizumab monotherapy for the management of head and neck squamous cell carcinoma (HNSCC) in the UKIfigenia Vasiliadou, Derek Grose, Christina Wilson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 23, 2023
Developing and Validating a Multivariable Prognostic-Predictive Classifier for Treatment Escalation of Oropharyngeal Squamous Cell Carcinoma: The PREDICTR-OPC StudyHisham Mehanna, Davy Rapozo, Sandra V von Zeidler, et al.
Pageof 4